Regenerex Pharma, Inc. (RGPX) Return on Investment ROI from the second quarter of 2025 to second quarter of 2024 and for the year 2025, average high and low, overall ranking from Sep 30 2025 to Sep 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
REGENEREX PHARMA, INC.  (OTC: RGPX)


Regenerex Pharma,'s ROI from its second quarter of 2025 to the second quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Regenerex Pharma,'s ROI in the second quarter of 2025?
Due to the stockholders deficit and subsequent negative measured investments, it was not possible to calculate Regenerex Pharma, Inc.'s return on investment (ROI) in its second quarter of 2025

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2025)
II. Quarter		 (Jun 30 2025)
I. Quarter		 (Mar 31 2025)
IV. Quarter		 (Dec 31 2024)
III. Quarter		 (Sep 30 2024)
II. Quarter
Y / Y Investment Change TTM - - - - -
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions -3 -3 -3 -5 -5
Return On Investment (TTM) - - - - -
RGPX's Overall Ranking # # # # #
Seq. Investment Change TTM - - - - -
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -1 -1 -1 -4 -4

RGPX Company Profile >> Back to RGPX Roi Comparisons >> See Annual RGPX Return On Investment



Return On Investment RGPX's Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Investment Statistics
High Average Low
0 %
0 %
0 %
 







Financial Statements
Regenerex Pharma,'s II. Quarter Investments $ -3 Millions RGPX's Balance sheet
Regenerex Pharma,'s II. Quarter Income $ -1 Millions Quarterly RGPX's Income Statement
RGPX's Income by Division See RGPX's Income by Division


RGPX Annual Return On Investment (Mar 31 2025)
2023		 (Mar 31 2022)
2022		 (Mar 31 2021)
2020		 (Mar 31 2020)
2019		 (Mar 31 2019)
2018
Total Investments in Millions -4 -1 -1 0 0
Y / Y Investment Growth - - - - -
Net Income in Millions -3 0 0 0 0
Y / Y Net Income Growth - - 217.03 % 19.23 % 88.33 %
Annual Return On Investment - - - - -


Annual Roi Comment
Despite deterioration in net income, company improved ROI to in the fiscal year 2023, company improved ROI to 88.33 % compare to previous year.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
RGPX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for RGPX's Competitors
Subscribers only: Roi for Regenerex Pharma,'s Suppliers
Subscribers only: Return On Investment for RGPX's Customers

Other Ratios
RGPX's Roa RGPX's Inventory Turnover Ratio RGPX's Growth Rates RGPX's Dividend Statistics
RGPX's Profitability Ratios RGPX's Asset Turnover Ratio RGPX's Dividend Growth
RGPX's Roe RGPX's Valuation Ratios RGPX's Financial Strength Ratios RGPX's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2025, within Healthcare Sector ROI
Kyntra Bio Inc   108.42 %
Oak Woods Acquisition Corp  106.75 %
Coherus Oncology inc   101.27 %
Stablecoin Development Corporation  94.92 %
Rigel Pharmaceuticals Inc  93.34 %
Silexion Therapeutics Corp  87.06 %
Interpace Biosciences Inc   77.75 %
Tg Therapeutics Inc   75.13 %
Arcutis Biotherapeutics Inc   71.66 %
Earth Science Tech Inc   68.50 %
Capforce Inc   65.08 %
Exelixis Inc   63.48 %
Cormedix Inc   56.64 %
Abeona Therapeutics Inc   55.42 %
Idexx Laboratories Inc  47.31 %
Adma Biologics Inc   44.57 %
Novavax inc   43.59 %
Ptc Therapeutics inc   43.15 %
Medinotec Inc   41.78 %
Dariohealth Corp   41.32 %
Entera Bio Ltd   37.53 %
Mettler toledo International Inc   35.51 %
Siga Technologies Inc  33.53 %
Cytomx Therapeutics Inc   33.34 %
Sbc Medical Group Holdings Incorporated  33.23 %
Halozyme Therapeutics Inc   32.75 %
Medpace Holdings Inc   31.78 %
Puma Biotechnology Inc   31.53 %
Eli Lilly And Company  31.20 %
Synlogic Inc   31.15 %

Date modified: 2026-09-12T06:28:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.